Editor’s summary Cancer immunotherapy is a type of treatment that mobilizes a patient’s immune system to kill tumor cells. It has been successful in treating
Abstract Cretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus
Highlights Summary Peripheral CD8+ T cell tolerance is a checkpoint in both autoimmune disease and anti-cancer immunity. Despite its importance, the relationship between tolerance-induced states and other
Significance The glycocalyx, a network of glycolipids and glycoproteins on cell surfaces, plays a pivotal role in immune modulation. Hypersialylated glycans have been identified as
Highlights Summary The therapeutic potential for human type 2 innate lymphoid cells (ILC2s) has been underexplored. Although not observed in mouse ILC2s, we found that
Abstract The peripheral T cell repertoire of healthy individuals contains self-reactive T cells1,2. Checkpoint receptors such as PD-1 are thought to enable the induction of
Abstract Despite no apparent defects in T cell priming and recruitment to tumors, a large subset of T cell rich tumors fail to respond to
Abstract Immunotherapy based on immunecheckpoint blockade (ICB) using antibodies induces rejection of tumours and brings clinical benefit in patients with various cancer types1. However, tumours
Highlights Summary Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor
Highlights Summary PSGL-1 (P-selectin glycoprotein-1) is a T cell-intrinsic checkpoint regulator of exhaustion with an unknown mechanism of action. Here, we show that PSGL-1 acts upstream
Highlights Summary Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the
Abstract Neoadjuvant ipilimumab + nivolumab (Ipi+Nivo) and nivolumab + chemotherapy (Nivo+CT) induce greater pathologic response rates than CT alone in patients with operable non-small cell
Abstract Metastatic breast cancer is an intractable disease that responds poorly to immunotherapy. We show that p38MAPKa inhibition (p38i) limits tumor growth by reprograming the
Abstract Neoantigens are peptides derived from non-synonymous mutations presented by human leukocyte antigens (HLAs), which are recognized by antitumour T cells1,2,3,4,5,6,7,8,9,10,11,12,13,14. The large HLA allele
Abstract BACKGROUND Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would
Dendritic cells save the day Dendritic cells are a key part of the immune system and are critical for antitumor immunity because they help to
Abstract Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses in the
Abstract Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment strategies to overcome resistance to cancer immunotherapy are lacking1,2. We identified
Abstract Breast cancer cells must avoid intrinsic and extrinsic cell death to relapse following chemotherapy. Entering senescence enables survival from mitotic catastrophe, apoptosis and nutrient
Preventing progression A subset of patients with melanoma treated with PD-1 blockade develop hyperprogression, where disease progresses more rapidly after treatment. Here, Theivanthiran et al. aimed to determine
Abstract Activation of scramblases is one of the mechanisms that regulates the exposure of phosphatidylserine to the cell surface, a process that plays an important
Abstract Mismatch repair-deficient (MMRd) cancers have varied responses to immune checkpoint blockade (ICB). We conducted a phase 2 clinical trial of the PD-1 inhibitor pembrolizumab
Highlights •Covalent K-Ras(G12C) inhibitors give rise to chemically modified cancer neoepitopes •Antibodies against these neoepitopes are identified by phage display •Bispecific antibodies induce T cell-mediated killing
Abstract In clinical settings, cancer vaccines as monotherapies have displayed limited success compared to other cancer immunotherapeutic treatments. Nanoscale formulations have the ability to increase
Highlights •Col1 produced by pancreatic cancer cells is the oncogenic homotrimer variant •Col1 homotrimer deletion in cancer cells inhibits pancreatic tumor progression •Col1 homotrimer deletion
Created by ePubSystems. Contact Us for similar site for your university or institute.